<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "76: products under development by", fill: "#cb4154"},
{source: "76: products under development by", target: "76: competitors", fill: "#cb4154"},
{source: "76: competitors", target: "76: clinical trials", fill: "#cb4154"},
{source: "76: clinical trials", target: "76: achievement", fill: "#cb4154"},
{source: "76: achievement", target: "76: regulatory approvals by", fill: "#cb4154"},
{source: "76: regulatory approvals by", target: "76: announcements", fill: "#cb4154"},
{source: "76: announcements", target: "76: technological", fill: "#cb4154"},
{source: "76: technological", target: "76: innovations", fill: "#cb4154"},
{source: "76: innovations", target: "76: new commercial", fill: "#cb4154"},
{source: "76: new commercial", target: "76: products by", fill: "#cb4154"},
{source: "76: products by", target: "76: developments concerning", fill: "#cb4154"},
{source: "76: developments concerning", target: "76: collaborations", fill: "#cb4154"},
{source: "76: collaborations", target: "76: regulatory developments", fill: "#cb4154"},
{source: "76: regulatory developments", target: "76: United States ", fill: "#cb4154"},
{source: "76: United States ", target: "76: external factors", fill: "#cb4154"},
{source: "76: external factors", target: "76: fluctuations", fill: "#cb4154"},
{source: "76: fluctuations", target: "76: operations", fill: "#cb4154"},
{source: "76: operations", target: "76: by securities analysts", fill: "#cb4154"},
{source: "76: by securities analysts", target: "76: selling activity", fill: "#cb4154"},
{source: "76: selling activity", target: "76: common stock", fill: "#cb4154"},
{source: "76: products under development by", target: "82: development", fill: "#f8f8ff"},
{source: "82: development", target: "82: early stage", fill: "#f8f8ff"},
{source: "82: development", target: "84: approval guidelines under", fill: "#ffb6c1"},
{source: "84: approval guidelines under", target: "84: to the FDA ", fill: "#ffb6c1"},
{source: "84: to the FDA ", target: "84: regulatory", fill: "#ffb6c1"},
{source: "84: regulatory", target: "84: requirements", fill: "#ffb6c1"},
{source: "84: approval guidelines under", target: "91: pharmaceutical", fill: "#bdda57"},
{source: "91: pharmaceutical", target: "91: possibility", fill: "#bdda57"},
{source: "91: possibility", target: "91: drug candidates will", fill: "#bdda57"},
{source: "91: drug candidates will", target: "91: safe nontoxic", fill: "#bdda57"},
{source: "91: safe nontoxic", target: "91: effective", fill: "#bdda57"},
{source: "91: effective", target: "91: otherwise meet applicable regulatory standards", fill: "#bdda57"},
{source: "91: otherwise meet applicable regulatory standards", target: "91: necessary regulatory approvals", fill: "#bdda57"},
{source: "91: necessary regulatory approvals", target: "91: into commercially viable drugs", fill: "#bdda57"},
{source: "91: into commercially viable drugs", target: "91: manufactured", fill: "#bdda57"},
{source: "91: manufactured", target: "91: economically", fill: "#bdda57"},
{source: "91: economically", target: "91: successfully marketed", fill: "#bdda57"},
{source: "91: successfully marketed", target: "91: reimbursed by government", fill: "#bdda57"},
{source: "91: reimbursed by government", target: "91: private insurers", fill: "#bdda57"},
{source: "91: private insurers", target: "91: customer acceptance", fill: "#bdda57"},
{source: "91: pharmaceutical", target: "94: immediately", fill: "#905d5d"},
{source: "94: immediately", target: "94: contingent", fill: "#905d5d"},
{source: "94: contingent", target: "94: the United States ", fill: "#905d5d"},
{source: "94: the United States ", target: "94: government", fill: "#905d5d"},
{source: "94: government", target: "94: collaborative", fill: "#905d5d"},
{source: "94: collaborative", target: "94: agreements", fill: "#905d5d"},
{source: "94: agreements", target: "94: revenues from", fill: "#905d5d"},
{source: "94: revenues from", target: "94: attain profitability", fill: "#905d5d"},
{source: "94: immediately", target: "99: earn significant", fill: "#8b0000"},
{source: "99: earn significant", target: "99: payments under", fill: "#8b0000"},
{source: "99: payments under", target: "99: collaborative", fill: "#8b0000"},
{source: "99: collaborative", target: "99: agreements", fill: "#8b0000"},
{source: "99: agreements", target: "99: collaborators", fill: "#8b0000"},
{source: "99: earn significant", target: "101: collaborative", fill: "#78184a"},
{source: "101: collaborative", target: "101: agreement", fill: "#78184a"},
{source: "101: agreement", target: "101: SBIR Grants ", fill: "#78184a"},
{source: "101: SBIR Grants ", target: "101: approximately", fill: "#78184a"},
{source: "101: collaborative", target: "START_HERE", fill: "#78184a"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cis-regulatory_element">Cis-regulatory element</a></td>
      <td>Cis-regulatory elements (CREs) or Cis-regulatory modules (CRMs) are regions of non-coding DNA which regulate the transcription of neighboring genes. CREs are vital components of genetic regulatory networks, which in turn control morphogenesis, the development of anatomy, and other aspects of embryonic development, studied in evolutionary developmental biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capitalism">Regulatory capitalism</a></td>
      <td>Regulatory capitalism suggests that the operation maintenance and development of the international political economy increasingly depends on administrative rules outside the legislatures and the courts. In other words, it tells us that capitalism is a regulatory institution – one that is being constituted, shaped, constrained and expanded as a historically woven patchwork of regulatory institutions, strategies, and functions.Although this patchwork varies widely across regions, nations, regimes, sectors, issues, and arenas, the general trend despite and beyond the process of liberalization is that of growth rather than decline of the role regulation in shaping policy and politics.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_writing">Collaborative writing</a></td>
      <td>Collaborative writing, or collabwriting is a method of group work that takes place in the workplace and in the classroom. Researchers expand the idea of collaborative writing beyond groups working together to complete a writing task.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_fiction">Collaborative fiction</a></td>
      <td>Collaborative fiction is a form of writing by a group of authors who share creative control of a story.\nCollaborative fiction can occur for commercial gain, as part of education, or recreationally – many collaboratively written works have been the subject of a large degree of academic research.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_software">Collaborative software</a></td>
      <td>Collaborative software or groupware is application software designed to help people working on a common task to attain their goals. One of the earliest definitions of groupware is "intentional group processes plus software to support them".As regards available interaction, collaborative software may be divided into: real-time collaborative editing platforms that allow multiple users to engage in live, simultaneous and reversible editing of a single file (usually a document),  and version control (also known as revision control and source control) platforms, which allow separate users to make parallel edits to a file, while preserving every saved edit by every user as multiple files (that are variants of the original file).Collaborative software is a broad concept that overlaps considerably with computer-supported cooperative work (CSCW).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_editing">Collaborative editing</a></td>
      <td>Collaborative editing is the editing of groups producing works together through individual contributions. Effective choices in group awareness, participation and coordination are critical to successful collaborative writing outcomes.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaborative_Fund">Collaborative Fund</a></td>
      <td>Collaborative Fund is a venture capital firm focused on providing seed and early stage funding to technology companies.\n\n\n== Firm ==\nFounded in 2010 by Craig Shapiro, the firm is based in New York City, New York, and manages approximately $250 million of investor capital.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Friday_Agreement">Good Friday Agreement</a></td>
      <td>The Good Friday Agreement (GFA), or Belfast Agreement (Irish: Comhaontú Aoine an Chéasta or Comhaontú Bhéal Feirste; Ulster-Scots: Guid Friday Greeance or Bilfawst Greeance), is a pair of agreements signed on 10 April 1998 that ended most of the violence of the Troubles, a political conflict in Northern Ireland that had ensued since the late 1960s. It was a major development in the Northern Ireland peace process of the 1990s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pursuit_of_Nazi_collaborators">Pursuit of Nazi collaborators</a></td>
      <td>The pursuit of Nazi collaborators refers to the post-World War II pursuit and apprehension of individuals who were not citizens of the Third Reich at the outbreak of World War II but collaborated with the Nazi regime during the war. Hence, this article does not cover former members of the NSDAP and their fates after the war.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Unofficial_collaborator">Unofficial collaborator</a></td>
      <td>An unofficial collaborator or IM (German: [iˈʔɛm] (listen); both from German inoffizieller Mitarbeiter), or euphemistically informal collaborator (informeller Mitarbeiter), was an informant in the German Democratic Republic (East Germany)  who delivered private information to the Ministry for State Security (MfS / Stasi). At the end of the East German government, there was a network of around 189,000 informants, working at every level of society.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bleiburg_repatriations">Bleiburg repatriations</a></td>
      <td>In May 1945, after the end of World War II in Europe, during which Yugoslavia had been occupied by the Axis powers, tens of thousands of soldiers and civilians associated with the Axis powers fled Yugoslavia to Austria as the Soviet Union (Red Army) and Yugoslav Partisans took control. When they reached Allied-occupied Austria, the British refused to accept their surrender and directed them to the Partisans instead despite knowing that they would be killed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Special_law_to_redeem_pro-Japanese_collaborators'_property">Special law to redeem pro-Japanese collaborators' property</a></td>
      <td>The special law to redeem pro-Japanese collaborators' property (Hanja: 親日反民族行為者財產의國家歸屬에關한特別法, literally "Special Law for the Nationalization of Pro-Japanese Race Traitors' Assets")  is a special South Korean law that passed the South Korean National Assembly on December 8, 2005, and was enacted on December 29, 2005. Under this law, the South Korean government is able to seize land and other properties owned by Korean collaborators (chinilpa), and their descendants, who supported the Japanese administration during the period between 1905 and 1945.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Paris_Agreement">Paris Agreement</a></td>
      <td>The Paris Agreement (French: Accord de Paris), often referred to as the Paris Accords or the Paris Climate Accords, is an international treaty on climate change, adopted in 2015. It covers climate change mitigation, adaptation, and finance.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Munich_Agreement">Munich Agreement</a></td>
      <td>The Munich Agreement (Czech: Mnichovská dohoda; Slovak: Mníchovská dohoda; German: Münchner Abkommen) was an agreement concluded at Munich on 30 September 1938, by Germany, the United Kingdom, France, and Italy. It provided "cession to Germany of the Sudeten German territory" of Czechoslovakia, despite the existence of a 1924 alliance agreement and 1925 military pact between France and the Czechoslovak Republic, for which it is also known as the Munich Betrayal (Mnichovská zrada; Mníchovská zrada).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Haavara_Agreement">Haavara Agreement</a></td>
      <td>The Haavara Agreement (Hebrew: הֶסְכֵּם הַעֲבָרָה‎  Translit.: heskem haavara   Translated: "transfer agreement") was an agreement between Nazi Germany and Zionist German Jews signed on 25 August 1933. The agreement was finalized after three months of talks by the Zionist Federation of Germany, the Anglo-Palestine Bank (under the directive of the Jewish Agency) and the economic authorities of Nazi Germany.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Schengen_Agreement">Schengen Agreement</a></td>
      <td>The Schengen Agreement (English:  SHENG-ən, Luxembourgish: [ˈʃæŋən] (listen)) is a treaty which led to the creation of Europe's Schengen Area, in which internal border checks have largely been abolished. It was signed on 14 June 1985, near the town of Schengen, Luxembourg, by five of the ten member states of the then European Economic Community.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>SIGA TECHNOLOGIES INC    Item 1A  <font color="blue">Risk Factors That May Affect Results of Operations </font>and            <font color="blue">Financial Condition</font></td>
    </tr>
    <tr>
      <td>11    Item 1A Risk Factors          This report  contains  forward-looking  statements  and other  prospective  information  relating to future  events</td>
    </tr>
    <tr>
      <td>These  forward-looking  statements and  other  information are subject to risks and  <font color="blue">uncertainties</font>  that could cause our  actual results to differ  <font color="blue">materially</font>  from our  historical  results or currently  anticipated results including the following:    We have  incurred  operating  losses since our inception and expect to incur net  losses and <font color="blue">negative cash flow</font> for the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">incurred net losses</font> of <font color="blue">approximately</font>  dlra2dtta3 million,  dlra9dtta4 million,  and  dlra5dtta3  million  for  the  years  ended   <font color="blue"><font color="blue">December </font> </font>31,  2005,   2004,  and  2003,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, 2004 and 2003, our  <font color="blue">accumulated</font>  deficit  was <font color="blue">approximately</font> dlra46dtta5 million, dlra44dtta2 million and dlra34dtta8 million,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We expect to continue to <font color="blue">incur <font color="blue">significant</font></font> operating <font color="blue"><font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>We will need  to <font color="blue">generate <font color="blue">significant</font> revenues</font> to achieve and maintain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We  cannot  guarantee  that  we  will  achieve  sufficient   revenues  for  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Even if we do achieve <font color="blue">profitability</font>, we cannot guarantee that we  can sustain or increase  <font color="blue">profitability</font>  on a  quarterly  or annual  basis in the  future</td>
    </tr>
    <tr>
      <td>If <font color="blue">revenues grow slower than</font> we  anticipate,  or if operating  expenses  exceed our  <font color="blue">expectations</font> or cannot be adjusted  <font color="blue">accordingly</font>,  then our business,  results of <font color="blue">operations</font>, <font color="blue">financial condition</font> and <font color="blue">cash flows will</font> be <font color="blue">materially</font> and  <font color="blue">adversely</font>  affected</td>
    </tr>
    <tr>
      <td>Because our <font color="blue">strategy might</font> include  <font color="blue">acquisitions</font>  of other  <font color="blue">businesses</font>,  acquisition  expenses and any cash used to make these  <font color="blue">acquisitions</font>  will reduce our <font color="blue">available cash</font></td>
    </tr>
    <tr>
      <td>11  <PAGE>    Our business will suffer if we are unable to <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> equity funding</font></td>
    </tr>
    <tr>
      <td>We  continue to be  <font color="blue">dependent</font>  on our ability to <font color="blue">raise money</font> in the equity  markets</td>
    </tr>
    <tr>
      <td>There is no guarantee that we <font color="blue">will continue</font> to be successful in raising  such funds</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">raise <font color="blue">additional</font></font>  <font color="blue">equity funds</font>, we may be forced  to  <font color="blue">discontinue</font>  or cease  certain  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  currently  have  sufficient  operating  capital to finance our  <font color="blue">operations</font>  beyond March 31, 2007</td>
    </tr>
    <tr>
      <td>Our annual  operating  needs  <font color="blue">vary from year</font> to year  depending  upon the  amount of revenue  generated  through  grants and licenses and the amount of projects we undertake,  as well as the amount of resources we expend,  in <font color="blue">connection</font>  with  <font color="blue">acquisitions</font>  all of which may  <font color="blue">materially</font>  <font color="blue">differ from year</font> to year and may <font color="blue">adversely</font>  affect  our business</td>
    </tr>
    <tr>
      <td>Our stock  price is, and we expect it to remain,  volatile,  which  could  limit  investors &amp;apos  ability to <font color="blue">sell stock at</font> a profit</td>
    </tr>
    <tr>
      <td>The  volatile  price of our stock  makes it  <font color="blue">difficult</font>  for  investors  to  predict the value of their  <font color="blue">investment</font>,  to <font color="blue">sell shares at</font> a profit at any given  time, or to plan purchases and sales in advance</td>
    </tr>
    <tr>
      <td>A variety of <font color="blue">factors may affect</font>  the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These include, but are not limited to:    o     publicity  regarding  actual or  potential  clinical  results  relating to        <font color="blue">products under <font color="blue">development</font> by</font> our <font color="blue">competitors</font> or us;    o     delay or failure in initiating,  completing or analyzing  pre-clinical  or        <font color="blue">clinical trials</font> or the unsatisfactory design or results of these trials;    o     <font color="blue">achievement</font> or rejection of <font color="blue"><font color="blue">regulatory</font> approvals by</font> our <font color="blue">competitors</font> or us;    o     <font color="blue">announcements</font> of <font color="blue">technological</font>  <font color="blue">innovations</font> or <font color="blue">new commercial</font>  <font color="blue">products by</font>        our <font color="blue">competitors</font> or us;    o     <font color="blue"><font color="blue">development</font>s concerning</font> <font color="blue">proprietary</font> rights, including patents;    o     <font color="blue"><font color="blue">development</font>s concerning</font> our <font color="blue">collaborations</font>;    o     <font color="blue"><font color="blue">regulatory</font> <font color="blue">development</font>s</font> in the <font color="blue">United States </font>and foreign countries;    o     economic or other crises and other <font color="blue">external factors</font>;    o     period-to-period  <font color="blue">fluctuations</font>  in  our  revenues  and  other  results  of        <font color="blue">operations</font>;    o     changes in financial estimates <font color="blue">by securities analysts</font>; and    o     sales and short <font color="blue">selling activity</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Additionally,  because there is not a <font color="blue">high volume</font> of trading in our stock,  any information about SIGA in the <font color="blue">media may</font> result in <font color="blue">significant</font>  <font color="blue">volatility</font> in  our stock price</td>
    </tr>
    <tr>
      <td>We will not be able to control many of these factors,  and we believe that  period-to-period  <font color="blue">comparisons</font> of our financial  results will not  <font color="blue">necessarily</font> be  <font color="blue">indicative</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general, and the market for <font color="blue">bio<font color="blue">technology</font></font>  companies in particular,  has experienced  <font color="blue">extreme price</font> and volume <font color="blue">fluctuations</font>  that may have <font color="blue">been unrelated</font> or <font color="blue">disproportionate</font> to the operating performance of  individual companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font> and <font color="blue">industry factors may seriously harm</font>  the <font color="blue">market price</font> of our <font color="blue">common stock</font>, regardless of our operating performance</td>
    </tr>
    <tr>
      <td>We are in <font color="blue">various stages</font> of <font color="blue">product <font color="blue">development</font></font> and there can be no assurance of  <font color="blue">successful <font color="blue">commercialization</font></font></td>
    </tr>
    <tr>
      <td>In general, our research and <font color="blue">development</font> programs are at an <font color="blue">early stage</font> of  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>To obtain FDA approval for our <font color="blue">biological warfare defense products</font>  we will be required to perform  two animal  models and provide  animal and human  <font color="blue">safety data</font></td>
    </tr>
    <tr>
      <td>Our other <font color="blue">products will</font> be subject to the <font color="blue">approval guidelines under</font>  FDA  <font color="blue">regulatory</font>  <font color="blue">requirements</font>  which  include a number of phases of  testing  in  humans</td>
    </tr>
    <tr>
      <td>12  <PAGE>          The FDA has not approved any of our <font color="blue">bio<font color="blue">pharmaceutical</font></font>  <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">drug <font color="blue">candidates</font></font> developed by us will require <font color="blue">significant</font> <font color="blue">additional</font> research  and <font color="blue">development</font> efforts,  including extensive  pre-clinical and <font color="blue">clinical testing</font>  and  <font color="blue">regulatory</font>  approval,  prior to  commercial  sale</td>
    </tr>
    <tr>
      <td>We  cannot  be sure our  approach to drug <font color="blue">discovery</font>  will be <font color="blue">effective</font> or will result in the  <font color="blue">development</font>  of any drug</td>
    </tr>
    <tr>
      <td>We cannot  expect that any drugs  resulting  from our research and  <font color="blue">development</font> efforts will be <font color="blue">commercially available</font> for many years, if at all</td>
    </tr>
    <tr>
      <td>We have limited experience in conducting pre-<font color="blue">clinical testing</font> and clinical  trials</td>
    </tr>
    <tr>
      <td>Even if we receive initially positive  pre-clinical or clinical results,  such  results do not mean that  similar  results  will be  obtained in the later  stages of drug  <font color="blue">development</font>,  <font color="blue">such as <font color="blue">additional</font></font>  pre-clinical  testing or human  <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>All of our potential <font color="blue">drug <font color="blue">candidates</font></font> are prone to the risks of  failure  inherent  in   <font color="blue">pharmaceutical</font>   product   <font color="blue">development</font>,   including  the  <font color="blue">possibility</font> that none of our <font color="blue">drug <font color="blue">candidates</font></font> will or can:          o     be safe, non-toxic and <font color="blue">effective</font>;          o     otherwise meet applicable <font color="blue">regulatory</font> standards;          o     receive the <font color="blue">necessary</font> <font color="blue">regulatory</font> approvals;          o     develop <font color="blue">into commercially viable drugs</font>;          o     be <font color="blue"><font color="blue">manufacture</font>d</font> or produced <font color="blue">economically</font> and on a large scale;          o     be <font color="blue"><font color="blue">successfully</font> marketed</font>;          o     be <font color="blue">reimbursed by <font color="blue">government</font></font> and <font color="blue">private insurers</font>; and          o     achieve <font color="blue">customer <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>In  addition,  third  parties  may  <font color="blue">preclude us from</font>  marketing  our drugs  through  <font color="blue">enforcement</font>  of their  <font color="blue">proprietary</font>  rights that we are not aware of, or  <font color="blue"><font color="blue">third parties</font> may</font> succeed in <font color="blue">marketing equivalent</font> or superior <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>Our  failure to develop safe, commercially viable drugs would have a material adverse  effect on our business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Most of our <font color="blue">immediately</font>  foreseeable  future revenues are <font color="blue">contingent</font> upon grants  and contracts from the <font color="blue">United States </font> <font color="blue">government</font> and  <font color="blue">collaborative</font>  and license  <font color="blue"><font color="blue">agreement</font>s</font> and we may not achieve  sufficient  <font color="blue">revenues from</font> these <font color="blue"><font color="blue">agreement</font>s</font> to  attain <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>Until and unless we <font color="blue">successfully</font>  make a product,  our ability to generate  revenues  will  largely   depend  on  our  ability  to  enter  into   <font color="blue">additional</font>  <font color="blue">collaborative</font>  <font color="blue"><font color="blue">agreement</font>s</font>,  strategic alliances,  research grants, contracts and  license  <font color="blue"><font color="blue">agreement</font>s</font>  with <font color="blue">third parties</font> and maintain the <font color="blue"><font color="blue">agreement</font>s</font> we currently  have in place</td>
    </tr>
    <tr>
      <td><font color="blue">Substantially  </font>all of our revenues for the years ended  <font color="blue"><font color="blue">December </font> </font>31, 2005,  2004 and 2003,  <font color="blue">respectively</font>,  were <font color="blue"><font color="blue">derived from</font> revenues</font>  related to  grants,  contracts and license  <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">current revenue</font> is <font color="blue">derived from</font>  contract  work  being  performed  for the NIH <font color="blue">under two major</font>  grants  which are  scheduled to expire in <font color="blue"><font color="blue">September </font> </font>2006 and  contracts  with the US  Army which  expire in <font color="blue"><font color="blue">September </font> </font>2006 and <font color="blue">December </font>2007</td>
    </tr>
    <tr>
      <td>These  <font color="blue"><font color="blue">agreement</font>s</font> are for specific  work to be  performed  under the  <font color="blue"><font color="blue">agreement</font>s</font>  and <font color="blue">could only</font> be  <font color="blue">canceled by</font> the  other <font color="blue">party thereto</font> for non-performance</td>
    </tr>
    <tr>
      <td>We may not earn <font color="blue">significant</font>  milestone  <font color="blue">payments under</font> our existing  <font color="blue">collaborative</font>  <font color="blue"><font color="blue">agreement</font>s</font>  until our  <font color="blue">collaborators</font>  have  advanced  products  into  clinical  testing,  which may not occur for many  years, if at all</td>
    </tr>
    <tr>
      <td>We have material <font color="blue"><font color="blue">agreement</font>s</font> with the following <font color="blue">collaborators</font>:          o     National  Institutes of Health</td>
    </tr>
    <tr>
      <td>Under our  <font color="blue">collaborative</font>  <font color="blue">agreement</font>              with the NIH we have  received  <font color="blue">SBIR Grants  </font>totaling  <font color="blue">approximately</font>              dlra11dtta1 million in 2004</td>
    </tr>
    <tr>
      <td>The term of these grants expire in <font color="blue"><font color="blue">September </font> </font>            2006</td>
    </tr>
    <tr>
      <td>We are paid as the work is performed and the <font color="blue">agreement</font> can be              cancelled for non-performance</td>
    </tr>
    <tr>
      <td>We also have an <font color="blue">agreement</font> whereby the              NIH is required to conduct  and pay for the  clinical  trials of our              <font color="blue">strep vaccine</font>  product  through  phase II <font color="blue">human trials</font></td>
    </tr>
    <tr>
      <td>We are current in all our              <font color="blue"><font color="blue">obligations</font> under</font> our <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>13  <PAGE>          o     United  States  Army  Medical  Research  and  Material  Command</td>
    </tr>
    <tr>
      <td>In              <font color="blue"><font color="blue">September </font> </font>2005 we <font color="blue">entered into</font> a dlra3dtta2  million,  one year  contract              with the USAMRMC  The <font color="blue">agreement</font>,  for the rapid  <font color="blue">identification</font> and              treatment of anti-viral  diseases, is <font color="blue">funded through</font> the USAF It is              anticipated  that our <font color="blue">efforts will aid</font> the USAF  Special  Operations              Command in its use of  <font color="blue">computational</font>  biology to design and  develop              specific  <font color="blue">countermeasures</font>  against biological threat agents <font color="blue"><font color="blue">Smallpox  </font>            </font>and  <font color="blue">Adenovirus</font></td>
    </tr>
    <tr>
      <td>We are  current in all our  <font color="blue">obligations</font>  under our              <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>On <font color="blue"><font color="blue">September </font> </font>1, 2005,  we <font color="blue">entered into</font> an              <font color="blue">agreement</font> with <font color="blue">Saint Louis University </font>for the continued  <font color="blue">development</font>              of one of our <font color="blue">Smallpox  </font>drugs</td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font> is funded  through the              NIH  Under the  <font color="blue">agreement</font>,  SIGA will  receive  <font color="blue">approximately</font>  dlra1dtta0              million  during the term of  <font color="blue">September </font>1, 2005 to <font color="blue">February </font>28, 2006</td>
    </tr>
    <tr>
      <td>We are current in all our <font color="blue"><font color="blue">obligations</font> under</font> our <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In              <font color="blue"><font color="blue">December </font> </font>2002, we <font color="blue">entered into</font> a <font color="blue">four year contract with</font> USAMRAA to              develop  a drug  to  treat  Smallpox</td>
    </tr>
    <tr>
      <td>We  are  current  in all  our              <font color="blue"><font color="blue">obligations</font> under</font> our <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The term of our <font color="blue">agreement</font> with <font color="blue">Rockefeller              </font>is for the duration of the patents and a number of pending  patents</td>
    </tr>
    <tr>
      <td>As we do not  currently  know  when any  patents  pending  or future              <font color="blue">patents will</font> expire, we <font color="blue">cannot at</font> this time  <font color="blue">definitively</font>  determine              the term of this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font> can be <font color="blue">terminated earlier</font>              if we are in breach of the  provisions  of the  <font color="blue">agreement</font> and do not              cure the breach in the allowed  cure  period</td>
    </tr>
    <tr>
      <td>We are current in all              <font color="blue"><font color="blue">obligations</font> under</font> the contract</td>
    </tr>
    <tr>
      <td>OSU is a signatory of our <font color="blue">agreement</font>  with              Rockefeller</td>
    </tr>
    <tr>
      <td>The term of this  <font color="blue">agreement</font> is for the duration of the              patents and a number of <font color="blue">pending patents</font></td>
    </tr>
    <tr>
      <td>As we do not currently know              when any <font color="blue">patents pending</font> or future <font color="blue">patents will</font> expire, we <font color="blue">cannot at</font>              this time  <font color="blue">definitively</font>  determine the term of this  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">The              </font><font color="blue">agreement</font>  can be  terminated  earlier  if we are in  breach  of the              provisions  of the  <font color="blue">agreement</font>  and do not  cure  the  breach  in the              <font color="blue">allowed cure</font>  period</td>
    </tr>
    <tr>
      <td>We are current in all  <font color="blue">obligations</font>  under the              contract</td>
    </tr>
    <tr>
      <td>We have also <font color="blue">entered into</font> a <font color="blue">subcontract</font> <font color="blue">agreement</font> with OSU              for us to  perform  work  under a grant  OSU has from  the NIH  <font color="blue">The              </font><font color="blue">subcontract</font>  <font color="blue">agreement</font> was renewable  annually and the <font color="blue">current terms</font>              <font color="blue">expired on</font> August 31, 2003</td>
    </tr>
    <tr>
      <td>Work on this <font color="blue">agreement</font> was completed in              2003</td>
    </tr>
    <tr>
      <td>We have licensed  certain  <font color="blue">technology</font>  from              <font color="blue">Washington </font>under a non-exclusive license <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The term of our              <font color="blue">agreement</font>  with  <font color="blue">Washington </font>is for the duration of the patents and a              number of  pending  patents</td>
    </tr>
    <tr>
      <td>As we do not  currently  know when any              patents  pending or future  <font color="blue">patents will</font>  expire,  we <font color="blue">cannot at</font> this              time  <font color="blue">definitively</font>  determine  the  term  of  this  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">The              </font><font color="blue">agreement</font>  cannot be  terminated  unless we fail to pay our share of              the  joint  patent  costs  for  the  <font color="blue">technology</font>  licensed</td>
    </tr>
    <tr>
      <td>We  have              <font color="blue">currently met</font> all our <font color="blue"><font color="blue">obligations</font> under</font> this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>o     Regents of the  <font color="blue">University of California</font></td>
    </tr>
    <tr>
      <td>We have licensed  certain              <font color="blue">technology</font> from Regents under an exclusive license <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We are              required  to <font color="blue">pay minimum</font>  royalties  under this  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We have              <font color="blue">currently met</font> all our <font color="blue"><font color="blue">obligations</font> under</font> this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Under  our  <font color="blue">collaborative</font>  <font color="blue">agreement</font>  with              TransTech Pharma, a related party, <font color="blue">TransTech Pharma </font>is <font color="blue">collaborating</font>              with  us on the  <font color="blue">discovery</font>,  <font color="blue">optimization</font>  and  <font color="blue">development</font>  of lead              compounds to certain  <font color="blue">therapeutic</font>  agents</td>
    </tr>
    <tr>
      <td>We and TransTech  Pharma              have agreed to share the costs of <font color="blue">development</font> and <font color="blue">revenues generated</font>              <font color="blue">from licensing</font> and <font color="blue">profits from</font> any  <font color="blue"><font color="blue">commercialize</font>d</font>  <font color="blue">products sales</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">agreement</font>  will be in effect until  <font color="blue">terminated by</font> the parties or              <font color="blue">upon cessation</font> of research or sales of all products  developed under              the  <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We  are  current  in  all  <font color="blue">obligations</font>  under  this              <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">bio<font color="blue">pharmaceutical</font></font>  market in which we  compete  and will  compete is highly  <font color="blue">competitive</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">bio<font color="blue">pharmaceutical</font></font>  industry is <font color="blue">characterized by rapid</font> and <font color="blue">significant</font>  <font color="blue">technological</font>  change</td>
    </tr>
    <tr>
      <td>Our  success  will  <font color="blue">depend on</font> our ability to develop and  apply our <font color="blue">technologies</font> in the design and <font color="blue">development</font> of our product                                             14  <PAGE>    <font color="blue">candidates</font>  and to establish  and maintain a market for our product  <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>There  also are  many  companies,  both  public  and  private,  including  major  <font color="blue">pharmaceutical</font>  and  chemical  companies,   specialized   <font color="blue">bio<font color="blue">technology</font></font>   firms,  <font color="blue">universities</font>   and   other   research   <font color="blue">institutions</font>   engaged   in   developing  <font color="blue">pharmaceutical</font>  and  <font color="blue">bio<font color="blue">technology</font></font>   products</td>
    </tr>
    <tr>
      <td>Many  of  these  companies  have  <font color="blue">substantially</font> greater financial,  technical, research and <font color="blue">development</font>, and human  resources than us</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>may develop products or other  <font color="blue">technologies</font> that  are more  <font color="blue">effective</font>  than any that are being  developed  by us or may obtain FDA  approval for products more <font color="blue">rapidly than us</font></td>
    </tr>
    <tr>
      <td>If we commence  commercial  sales of  products,  we <font color="blue">still must</font>  compete in the  <font color="blue">manufacturing</font>  and  marketing  of such  products,  areas in which we have no  experience</td>
    </tr>
    <tr>
      <td>Many of these  companies also  have <font color="blue">manufacturing</font>  <font color="blue">facilities</font> and established marketing <font color="blue">capabilities</font> that would  enable such companies to market competing  products through existing channels of  <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>Two <font color="blue">companies with</font> similar  profiles are VaxGen,  Inc,  which is  developing   vaccines  against  anthrax,   <font color="blue">Smallpox  </font>and  HIV/AIDS;   and  Avant  Immuno<font color="blue">therapeutic</font>s,  Inc,  which has vaccine  programs for agents of biological  warfare</td>
    </tr>
    <tr>
      <td>Because we must obtain  <font color="blue">regulatory</font>  clearance to test and market our products in  the United  States,  we cannot  predict  whether or when we will be permitted to  <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>A  <font color="blue">pharmaceutical</font>  product  cannot be  marketed  <font color="blue">in the US </font> until it has  completed  rigorous  pre-clinical  testing and clinical  trials and an extensive  <font color="blue">regulatory</font>  <font color="blue">clearance process</font>  <font color="blue">implemented by</font> the FDA  Pharmaceutical  products  typically  take many years to satisfy  <font color="blue">regulatory</font>  <font color="blue">requirements</font>  and require the  <font color="blue">expenditure</font>  of  substantial  resources  <font color="blue">depending on</font> the type,  <font color="blue">complexity</font>  and  novelty of the product</td>
    </tr>
    <tr>
      <td>Before  commencing  <font color="blue">clinical trials</font> in humans,  we must submit and receive  clearance  from  the FDA by means of an IND  <font color="blue">application</font></td>
    </tr>
    <tr>
      <td><font color="blue">Institutional  </font>review  boards and the FDA oversee <font color="blue">clinical trials</font> and such trials:          o     must be  conducted  in  conformance  with the FDAapstas good  <font color="blue">laboratory</font>              <font color="blue">practice <font color="blue">regulations</font></font>;          o     must meet <font color="blue">requirements</font> for <font color="blue">institutional review board oversight</font>;          o     must meet <font color="blue">requirements</font> for <font color="blue">informed consent</font>;          o     must  meet   <font color="blue">requirements</font>   for  good  clinical  and   <font color="blue">manufacturing</font>              practices;          o     are subject to continuing FDA oversight;          o     may require large numbers of <font color="blue">test subjects</font>; and          o     may be <font color="blue">suspended by us</font> or the FDA at any time if it is believed that              the  subjects  <font color="blue">participating</font>  in these  trials are being  exposed to              unacceptable  <font color="blue">health risks</font> or if the FDA finds  <font color="blue">deficiencies</font>  in the              IND <font color="blue">application</font> or the conduct of these trials</td>
    </tr>
    <tr>
      <td>Before  receiving FDA clearance to market a product,  we must  <font color="blue">demonstrate</font>  that the product is safe and  <font color="blue">effective</font> on the patient  population  that will be  treated</td>
    </tr>
    <tr>
      <td>Data we obtain <font color="blue">from preclinical</font> and <font color="blue">clinical <font color="blue">activities</font></font> are susceptible  to  varying  <font color="blue">interpretations</font>  that  could  delay,  limit or  prevent  <font color="blue">regulatory</font>  <font color="blue">clearances</font></td>
    </tr>
    <tr>
      <td>Additionally, we have limited experience in conducting and managing  the <font color="blue">clinical trials</font> and <font color="blue">manufacturing</font>  processes  <font color="blue">necessary</font> to obtain <font color="blue">regulatory</font>  clearance</td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font>  clearance of a product is granted,  this  <font color="blue">clearance will</font> be  limited  only  to  those  states  and   <font color="blue">conditions</font>  for  which  the  product  is  <font color="blue">demonstrate</font>d  through  clinical  trials  to be safe and  <font color="blue">efficacious</font></td>
    </tr>
    <tr>
      <td>We cannot  ensure that any compound developed by us, alone or with others, will prove to be  safe and  <font color="blue">efficacious</font>  in  clinical  trials and will meet all of the  applicable  <font color="blue">regulatory</font> <font color="blue">requirements</font> needed to receive <font color="blue">marketing clearance</font></td>
    </tr>
    <tr>
      <td>If our  <font color="blue">technologies</font>  or  those of our  <font color="blue">collaborators</font>  are  alleged  or found to  infringe the patents or <font color="blue">proprietary</font>  rights of others, we may be sued or have to  license those <font color="blue">rights from others on unfavorable terms</font></td>
    </tr>
    <tr>
      <td>Our commercial <font color="blue">success will depend</font> <font color="blue">significant</font>ly on our ability to operate  without  infringing the patents and  <font color="blue">proprietary</font>  rights of third  parties</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">technologies</font>, along with our <font color="blue">licensors</font> &amp;apos  and our <font color="blue">collaborators</font> &amp;apos  <font color="blue">technologies</font>, may  infringe  the patents or  <font color="blue">proprietary</font>  rights of others</td>
    </tr>
    <tr>
      <td>If there is an adverse  outcome  in  <font color="blue">litigation</font>  or an  <font color="blue">interference</font>  to  determine  priority  or  other  proceeding  in a court or  patent  office,  then we,  or our  <font color="blue">collaborators</font>  and  <font color="blue">licensors</font>,  could be subjected to <font color="blue">significant</font>  <font color="blue">liabilities</font>,  required to license  disputed  rights  from or to other  parties                                             15  <PAGE>    and/or  required to <font color="blue">cease using</font> a <font color="blue">technology</font>  <font color="blue">necessary</font>  to carry out  research,  <font color="blue">development</font> and <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>At present we are unaware of any or potential  <font color="blue">infringement</font> claims against our <font color="blue">patent portfolio</font></td>
    </tr>
    <tr>
      <td>The costs to establish the validity of patents,  to defend  <font color="blue">against patent</font>  <font color="blue">infringement</font>  claims of others and to assert  <font color="blue">infringement</font> claims <font color="blue">against others</font>  can be  expensive  and time  consuming,  even if the  outcome is  favorable</td>
    </tr>
    <tr>
      <td>An  outcome of any <font color="blue">patent prosecution</font> or <font color="blue">litigation</font> that is unfavorable to us or one  of our <font color="blue">licensors</font> or  <font color="blue">collaborators</font>  may have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>We  <font color="blue">could incur</font>  substantial  costs if we are required to <font color="blue">defend ourselves</font> in patent  suits  brought by third  parties,  if we  <font color="blue">participate</font>  in patent  suits  brought  against or <font color="blue">initiated by</font> our  <font color="blue">licensors</font> or  <font color="blue">collaborators</font>  or if we <font color="blue">initiate such</font>  suits</td>
    </tr>
    <tr>
      <td>We may not have <font color="blue">sufficient funds</font> or resources in the event of <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Additionally, we may not prevail in any <font color="blue">such action</font></td>
    </tr>
    <tr>
      <td>Any conflicts  resulting from third-party patent  <font color="blue">application</font>s and patents  could  <font color="blue">significant</font>ly  reduce the coverage of the patents  owned,  <font color="blue">optioned by</font> or  licensed  to us or our  <font color="blue">collaborators</font>  and  limit  our  ability  or  that of our  <font color="blue">collaborators</font> to obtain <font color="blue">meaningful patent</font>  protection</td>
    </tr>
    <tr>
      <td>If patents are issued to  <font color="blue">third parties</font> that contain  <font color="blue">competitive</font> or <font color="blue">conflicting</font> claims, we, our <font color="blue">licensors</font>  or our <font color="blue">collaborators</font> may be legally  <font color="blue">prohibited from researching</font>,  developing or  <font color="blue">commercializing</font> of <font color="blue">potential products</font> or be required to obtain licenses to these  patents or to develop or obtain alternative <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We, our <font color="blue">licensors</font> and/or  our <font color="blue">collaborators</font> may be legally prohibited from using patented <font color="blue">technology</font>,  may  not be able to obtain  any  license to the  patents  and  <font color="blue">technologies</font>  of third  <font color="blue">parties on</font> acceptable  terms, if at all, or may not be able to obtain or develop  alternative <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>In addition,  like many <font color="blue">bio<font color="blue">pharmaceutical</font></font>  companies,  we may from time to  time <font color="blue">hire scientific</font>  <font color="blue">personnel formerly employed by</font> other <font color="blue">companies involved</font> in  one or more areas  similar to the  <font color="blue">activities</font>  conducted  by us</td>
    </tr>
    <tr>
      <td>We and/or these  <font color="blue">individuals</font>  may be subject to <font color="blue">allegations</font> of <font color="blue">trade secret</font>  <font color="blue">misappropriation</font>  or  other similar claims as a result of their <font color="blue">prior affiliations</font></td>
    </tr>
    <tr>
      <td>Our  ability  to  compete  may  decrease  if we do not  <font color="blue">adequately</font>  protect  our  <font color="blue">intellectual property rights</font></td>
    </tr>
    <tr>
      <td>Our commercial  <font color="blue">success will depend</font> in part on our and our  <font color="blue">collaborators</font> &amp;apos   ability  to  obtain  and  maintain   patent   protection  for  our   <font color="blue">proprietary</font>  <font color="blue">technologies</font>,  <font color="blue">drug targets</font> and potential  products and to <font color="blue">effective</font>ly  preserve  our  trade  secrets</td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>of the  substantial  length  of time and  expense  associated  with  bringing   potential  products  through  the  <font color="blue">development</font>  and  <font color="blue">regulatory</font>  clearance  processes to reach the  marketplace,  the  <font color="blue">pharmaceutical</font>  industry  places  considerable  <font color="blue">importance on</font> obtaining  patent and <font color="blue">trade secret</font>  protection</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">technology</font></font>  companies  can be highly  uncertain  and involve  <font color="blue">complex legal</font> and factual  questions</td>
    </tr>
    <tr>
      <td>No  <font color="blue">consistent</font>  policy  regarding  the  breadth of claims  allowed in  <font color="blue">bio<font color="blue">technology</font></font>  patents has emerged to date</td>
    </tr>
    <tr>
      <td>Accordingly, we <font color="blue">cannot predict</font> the type and breadth  of claims allowed in these patents</td>
    </tr>
    <tr>
      <td>We have licensed the rights to <font color="blue">eight issued</font> US  patents and <font color="blue">three issued</font>  <font color="blue">European  </font>patents</td>
    </tr>
    <tr>
      <td>These patents have <font color="blue">varying lives</font> and they are related to the  <font color="blue">technology</font> licensed from Rockefeller  University for the Strep and Gram-positive  products</td>
    </tr>
    <tr>
      <td>We  have  one  <font color="blue">additional</font>  patent  <font color="blue">application</font>  in the  US  and one  <font color="blue">application</font>  <font color="blue">in Europe  </font>relating  to this  <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We are joint  owner with  <font color="blue">Washington </font> University of seven issued patents <font color="blue">in the US </font>and one in Europe</td>
    </tr>
    <tr>
      <td>In  addition,  there are four co-owned US patent  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>These patents are  for the <font color="blue">technology</font> used for the Gram-negative <font color="blue">product <font color="blue">opportunities</font></font></td>
    </tr>
    <tr>
      <td>We are also  <font color="blue">exclusive owner</font> of one US patent and three US  patent  <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>One of  these US patent <font color="blue">application</font>s relates to our DegP <font color="blue">product <font color="blue">opportunities</font></font></td>
    </tr>
    <tr>
      <td>We included a summary of out patent  positions  as of <font color="blue">December </font>31, 2005 in  Part I, Item 1 of this document</td>
    </tr>
    <tr>
      <td>We also rely on copyright protection, <font color="blue">trade secret</font>s, know-how,  continuing  <font color="blue">technological</font> innovation and licensing  <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>In an effort to maintain  the <font color="blue"><font color="blue">confidential</font>ity</font> and ownership of <font color="blue">trade secret</font>s and <font color="blue">proprietary</font>  information,  we  require  our  employees,  <font color="blue">consultants</font>  and  some  <font color="blue">collaborators</font>  to  execute  <font color="blue"><font color="blue">confidential</font>ity</font>  and invention  <font color="blue">assignment</font>  <font color="blue"><font color="blue">agreement</font>s</font>  upon  <font color="blue">commencement</font>  of a  <font color="blue">relationship with us</font></td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">agreement</font>s</font> may not <font color="blue">provide meaningful protection</font> for  our  trade  secrets,  <font color="blue">confidential</font>  information  or  <font color="blue">inventions</font>  in the event of  <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font> of such  information,  and adequate  <font color="blue">remedies may</font>  not exist in the event of such <font color="blue">unauthorized use</font> or <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>16  <PAGE>    We may have <font color="blue">difficult</font>y managing our growth</td>
    </tr>
    <tr>
      <td>We expect to  experience  growth in the  number of our  employees  and the  scope of our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">future growth could</font> place a <font color="blue">significant</font> strain on  our  <font color="blue">management</font>  and  <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to manage this <font color="blue">growth will depend</font>  upon our ability to broaden our <font color="blue">management</font> team and our ability to attract, hire  and retain <font color="blue">skilled employees</font></td>
    </tr>
    <tr>
      <td>Our success will also <font color="blue">depend on</font> the ability of our  officers and <font color="blue">key employees</font> to continue to implement and improve our  operational  and other systems and to hire, train and manage our employees</td>
    </tr>
    <tr>
      <td>Our <font color="blue">activities</font>  <font color="blue">involve <font color="blue">hazardous</font></font>  materials and may subject us to <font color="blue">environmental</font>  <font color="blue">regulatory</font> <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">bio<font color="blue">pharmaceutical</font></font> research and <font color="blue">development</font> involves the <font color="blue">controlled use</font>  of <font color="blue">hazardous</font> and <font color="blue">radioactive</font>  materials and biological  waste</td>
    </tr>
    <tr>
      <td>We are subject to  federal,  state and <font color="blue">local laws</font> and <font color="blue">regulations</font>  governing the use,  <font color="blue">manufacture</font>,  storage,  handling and disposal of these  materials and <font color="blue">certain waste</font>  products</td>
    </tr>
    <tr>
      <td>Although we believe that our safety  procedures  for  handling and  disposing of  these <font color="blue">materials <font color="blue">comply with</font> legally prescribed standards</font>, the risk of <font color="blue"><font color="blue">accident</font>al</font>  <font color="blue">contamination</font> or <font color="blue">injury from</font> these <font color="blue">materials cannot</font> be <font color="blue">completely eliminated</font></td>
    </tr>
    <tr>
      <td>In  the  event of an  <font color="blue">accident</font>,  we  could  be held  liable  for  damages,  and this  <font color="blue"><font color="blue">liability</font> could exceed</font> our resources</td>
    </tr>
    <tr>
      <td>The research and <font color="blue">development</font> <font color="blue">activities</font> of  our  company do not  produce any  unusual  <font color="blue">hazardous</font>  products</td>
    </tr>
    <tr>
      <td>We do use small  amounts of 32P, 35S and 3H, which are stored, used and disposed of in <font color="blue">accordance</font>  with Nuclear Regulatory  Commission ( &amp;quote NRC &amp;quote )  <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>We maintain <font color="blue">liability</font>  insurance in the amount of  <font color="blue">approximately</font>  dlra5cmam000cmam000 and we believe this should  be sufficient to cover any <font color="blue">contingent</font> losses</td>
    </tr>
    <tr>
      <td>We  believe  that  we are in  compliance  in all  material  respects  with  applicable  <font color="blue">environmental</font>  laws and  <font color="blue">regulations</font>  and currently do not expect to  make  material  <font color="blue">additional</font>  capital   <font color="blue"><font color="blue">expenditure</font>s</font>  for  <font color="blue">environmental</font>   control  <font color="blue">facilities</font> in the near term</td>
    </tr>
    <tr>
      <td>However, we may have to <font color="blue">incur <font color="blue">significant</font></font> costs to  <font color="blue"><font color="blue">comply with</font> current</font> or future <font color="blue">environmental</font> laws and <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential products</font> may not be acceptable in the market or eligible for third  party  <font color="blue">reimbursement</font>  resulting  in a negative  <font color="blue">impact on</font> our  future  financial  results</td>
    </tr>
    <tr>
      <td>Any products  <font color="blue">successfully</font>  developed by us or our <font color="blue">collaborative</font>  partners  may  not  achieve  market  <font color="blue">acceptance</font></td>
    </tr>
    <tr>
      <td>The  antibiotic  products  which  we are  attempting to develop <font color="blue">will compete with</font> a number of well-established traditional  <font color="blue">antibiotic drugs</font>  <font color="blue"><font color="blue">manufacture</font>d</font> and <font color="blue">marketed by major</font>  <font color="blue">pharmaceutical</font>  companies</td>
    </tr>
    <tr>
      <td>The degree of market  <font color="blue">acceptance</font>  of any of our <font color="blue">products will</font> <font color="blue">depend on</font> a number  of factors, including:          o     the  <font color="blue">establishment</font> and <font color="blue">demonstration</font> in the <font color="blue">medical community</font> of the              <font color="blue">clinical efficacy</font> and safety of such products,          o     the potential  advantage of such  products  <font color="blue">over existing</font>  treatment              methods, and          o     <font color="blue">reimbursement</font> policies of <font color="blue">government</font> and third-party payors</td>
    </tr>
    <tr>
      <td>Physicians, patients or the <font color="blue">medical community</font> in <font color="blue">general may</font> not accept or  utilize any products  that we or our  <font color="blue">collaborative</font>  partners  may develop</td>
    </tr>
    <tr>
      <td>Our  ability to receive revenues and income with respect to drugs, if any,  developed  through the use of our <font color="blue">technology</font> will depend, in part, upon the extent to which  <font color="blue">reimbursement</font>  for the cost of such drugs  will be  available  from  third-party  payors,  such as <font color="blue">government</font> health  <font color="blue">administration</font>  <font color="blue">authorities</font>,  <font color="blue">private health</font>  <font color="blue">care insurers</font>,  <font color="blue">health maintenance</font>  <font color="blue">organizations</font>,  pharmacy benefits <font color="blue">management</font>  companies and other <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Third-party payors are <font color="blue">increasingly disputing</font>  the <font color="blue">prices charged</font> for <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td>If third-party <font color="blue">reimbursement</font> was  not available or sufficient  to allow  profitable  <font color="blue">price levels</font> to be maintained  for drugs  developed by us or our  <font color="blue">collaborative</font>  partners,  it could  <font color="blue">adversely</font>  affect our business</td>
    </tr>
    <tr>
      <td>If our <font color="blue">products harm</font> people, we may experience product <font color="blue">liability</font> claims that may  not be <font color="blue">covered by insurance</font></td>
    </tr>
    <tr>
      <td>We  face an  inherent  business  risk of  exposure  to  potential  product  <font color="blue">liability</font> claims in the event that drugs we develop are alleged to cause adverse  effects  on  patients</td>
    </tr>
    <tr>
      <td>Such risk  exists  for  products  being  tested in human  clinical  trials,  <font color="blue">as well as products</font>  that  receive  <font color="blue">regulatory</font>  approval  for  <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>We may seek to obtain product <font color="blue">liability</font>  <font color="blue">insurance with respect</font>  to drugs we and/or or our <font color="blue">collaborative</font> partners develop</td>
    </tr>
    <tr>
      <td>However, we may                                             17  <PAGE>    not be able to obtain <font color="blue">such insurance</font></td>
    </tr>
    <tr>
      <td>Even if <font color="blue">such insurance</font> is obtainable,  it  may not be <font color="blue">available at</font> a reasonable  cost or in a sufficient  amount to protect  us against <font color="blue">liability</font></td>
    </tr>
    <tr>
      <td>We may be required to perform <font color="blue">additional</font>  <font color="blue">clinical trials</font> or change the labeling  of our products if we or others  identify side effects after our products are on  the market, which could harm sales of the <font color="blue">affected products</font></td>
    </tr>
    <tr>
      <td>If we or others  identify  side  effects  after any of our products on the  market, or if <font color="blue">manufacturing</font> problems occur:          o     <font color="blue">regulatory</font> approval may be withdrawn;          o     <font color="blue">reformulation</font> of our products,  <font color="blue">additional</font> <font color="blue">clinical trials</font>,  changes              in labeling of our <font color="blue">products may</font> be required;          o     changes to or  re-approvals of our  <font color="blue">manufacturing</font>  <font color="blue">facilities</font> may be              required;          o     sales of the <font color="blue">affected products</font> may drop <font color="blue">significant</font>ly;          o     our reputation in the <font color="blue">marketplace may suffer</font>; and          o     lawsuits, including class action suits, may be <font color="blue">brought against us</font></td>
    </tr>
    <tr>
      <td>Any of the above  <font color="blue">occurrences</font>  could harm or <font color="blue">prevent sales</font> of the affected  products  or could  increase  the  costs and  expenses  of  <font color="blue">commercializing</font>  and  marketing these products</td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacture</font> of <font color="blue">bio<font color="blue">technology</font></font>  products can be a  time-consuming  and complex  <font color="blue">process which may delay</font> or prevent  <font color="blue">commercialization</font>  of our  products,  or may  prevent  our  ability  to  produce  an  adequate   volume  for  the   successful  <font color="blue">commercialization</font> of our products</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">management</font>  believes  that we have the  ability to acquire or produce  quantities of products  sufficient to support our present needs for research and  our  projected  needs  for  our  initial  clinical  <font color="blue">development</font>  programs</td>
    </tr>
    <tr>
      <td>The  <font color="blue">manufacture</font> of all of our <font color="blue">products will</font> be subject to current Good Manufacturing  Practices (GMP) <font color="blue">requirements</font> prescribed by the FDA or other <font color="blue">standards prescribed</font>  by the  <font color="blue">appropriate</font>  <font color="blue">regulatory</font>  agency in the  country of use</td>
    </tr>
    <tr>
      <td>There can be no  assurance  that  we  will be able  to  <font color="blue">manufacture</font>  products,  or have  products  <font color="blue"><font color="blue">manufacture</font>d</font> for us, in a <font color="blue">timely fashion at</font> acceptable quality and prices,  that  we or <font color="blue">third party</font>  <font color="blue">manufacture</font>rs  can <font color="blue">comply with</font> GMP, or that we or <font color="blue">third party</font>  <font color="blue">manufacture</font>rs will be able to <font color="blue">manufacture</font> an adequate supply of product</td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare  </font>reform and  <font color="blue">controls on</font>  healthcare  <font color="blue">spending may limit</font> the price we  charge for any products and the <font color="blue">amounts thereof</font> that we can sell</td>
    </tr>
    <tr>
      <td>The US  federal  <font color="blue">government</font> and <font color="blue">private insurers</font> have considered ways to  change, and have changed,  the manner in <font color="blue">which healthcare</font>  services are provided  <font color="blue">in the US </font>Potential approaches and changes in <font color="blue">recent years</font> include <font color="blue">controls on</font>  healthcare  spending and the creation of large <font color="blue">purchasing groups</font></td>
    </tr>
    <tr>
      <td>In the future,  the US  <font color="blue">government</font> may institute  further  controls and <font color="blue">limits on</font> Medicare and  Medicaid spending</td>
    </tr>
    <tr>
      <td>These controls and <font color="blue">limits might affect</font> the payments we could  <font color="blue">collect from sales</font> of any products</td>
    </tr>
    <tr>
      <td><font color="blue">Uncertainties  </font>regarding future  healthcare  reform and <font color="blue">private market</font>  practices could <font color="blue">adversely</font>  affect our ability to sell  any <font color="blue">products profitably</font> <font color="blue">in the US </font>At present, we do not foresee any changes in  FDA <font color="blue">regulatory</font> policies that would <font color="blue">adversely</font> affect our <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>The future  issuance of preferred  stock may <font color="blue">adversely</font>  affect the rights of the  holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">certificate</font> of <font color="blue">incorporation allows</font> our <font color="blue">Board of Directors </font>to issue up  to  10cmam000cmam000  shares  of  preferred  stock  and  to  fix  the  voting  powers,  <font color="blue">designations</font>,   <font color="blue">preferences</font>,   rights   and   <font color="blue">qualifications</font>,   <font color="blue">limitations</font>   or  <font color="blue">restrictions</font>  of  these  shares  without  any  further  vote  or  action  by the  <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the holders of <font color="blue">common stock</font> will be subject to, and  could be <font color="blue">adversely</font> affected by, the rights of the holders of any <font color="blue">preferred stock</font>  that we may  issue  in the  future</td>
    </tr>
    <tr>
      <td>The  issuance  of  preferred  stock,  while  <font color="blue">providing desirable flexibility</font> in <font color="blue">connection</font> with possible                                             18  <PAGE>    <font color="blue">acquisitions</font>  and other corporate  purposes,  could have the effect of making it  more <font color="blue">difficult</font> for a <font color="blue">third party</font> to acquire a majority of our <font color="blue">outstanding voting</font>  stock, thereby delaying, deferring or preventing a change in control</td>
    </tr>
    <tr>
      <td><font color="blue">Concentration </font>of ownership of our capital stock could delay or prevent change of  control</td>
    </tr>
    <tr>
      <td>Our <font color="blue">directors</font>,  <font color="blue">executive officers</font> and principal <font color="blue">stockholders</font> <font color="blue">beneficially</font>  own a <font color="blue">significant</font>  percentage of our <font color="blue">common stock</font> and <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>They also  have,  through the exercise or  <font color="blue">conversion</font> of certain  securities,  the right to  acquire  <font color="blue">additional</font>  <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result,  these  <font color="blue">stockholders</font>,  if acting  together,  have the ability to <font color="blue">significant</font>ly  influence the outcome of corporate  actions requiring  <font color="blue">shareholder</font>  approval</td>
    </tr>
    <tr>
      <td>Additionally,  this  <font color="blue">concentration</font> of  ownership  may have the effect of delaying or  preventing a change in control of  SIGA  At <font color="blue">December </font>31, 2005,  Directors,  Officers  and  principal  <font color="blue">stockholders</font>  <font color="blue">beneficially</font> owned <font color="blue">approximately</font> 46dtta0prca of our stock</td>
    </tr>
  </tbody>
</table>